Abstract：Objective To evaluate the value of radiotherapy following rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)-based chemotherapy for patients with early-stage Waldeyer’s ring diffuse large B-cell lymphoma (WR-DLBCL). Methods Eighty-three patients diagnosed with early-stage WR-DLBCL who were admitted to our hospital from 2000 to 2013 were enrolled in the study. In these patients, twenty-five had stage Ⅰ disease and fifty-eight had stage Ⅱ disease. All patients received R-CHOP-based chemotherapy with (n=62) or without (n=21) involved-field radiotherapy (Waldeyer’s ring plus cervical lymph nodes). The overall survival (OS), progression-free survival (PFS), and local-regional control (LRC) rates were calculated using the Kaplan-Meier method. The univariate analysis was performed using the log-rank method. The multivariate analysis was performed using the Cox regression model. Results In all patients, the 5-year sample size was 18;the 5-year OS, PFS, and LRC rates were 89%, 84%, and 90%, respectively. According to the univariate analysis, patient age greater than 60 years, an increased lactate dehydrogenase level, Eastern Cooperative Oncology Group (ECOG) performance status no less than 2, and International Prognostic Index (IPI) no less than 2 were poor prognostic factors. Patient age greater than 60 years, a tumor size no less than 5 cm, ECOG performance status no less than 2, and IPI no less than 2 were influencing factors for PFS and LRC rates. In addition to the treatment with rituximab, patients treated with consolidative radiotherapy had significantly higher PFS and LRC rates (94% vs. 58%, P=0.003;100% vs. 61%, P=0.000) as well as slightly higher OS rate(94% vs. 71%,P=0.063) than those treated without radiotherapy. Conclusions Consolidative radiotherapy following R-CHOP-based chemotherapy significantly improves PFS, LRC, and probably OS rates for early-stage WR-DLBCL. This conclusion still needs to be confirmed by prospective studies with a large sample size.
Xu Yonggang,Li Yexiong,Wang Weihu et al. Value of radiotherapy for early-stage Waldeyer’s ring diffuse large B-cell lymphoma in the rituximab era[J]. Chinese Journal of Radiation Oncology, 2015, 24(5): 502-505.
[1] Coiffier B,Lepage E,Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma[J]. N Engl J Med,2002,346(4):235-242. [2] Pfreundschuh M,Trümper L,Osterborg A,et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma:a randomised controlled trial by the MabThera International Trial (MInT) Group[J]. Lancet Oncol,2006,7(5):379-391. [3] Pfreundschuh M,Schubert J,Ziepert M,et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas:a randomised controlled trial (RICOVER-60)[J]. Lancet Oncol,2008,9(1):105-116.DOI:10.1016/S1470-2045(08)70002-0. [4] Illidge T, Specht L, Yahalom J, et al. Modern radiation therapy for nodal non-Hodgkin lymphoma:target definition and dose guidelines from the International Lymphoma Radiation Oncology Group[J]. Int J Radiat Oncol Biol Phys,2014,89(1):49-58. DOI:10.1016/j.ijrobp.2014.01.006. [5] 李晔雄,高远红,袁智勇,等.国际预后指数在韦氏环非霍奇金淋巴瘤的预后意义[J].中华放射肿瘤学杂志,2002,11(2):105-110. [6] Qi SN, Li YX, Wang H,et al. Diffuse large B-cell lymphoma:clinical characterization and prognosis of Waldeyer ring versus lymph node presentation[J].Cancer,2009,115(21):4980-4989. DOI:10.1002/cncr.24557. [7] Wu RY, Li YX, Wang WH, et al. Clinical disparity and favorable prognoses for patients with Waldeyer ring extranodal nasal-type NK/T-cell lymphoma and diffuse large B-cell lymphoma[J]. Am J Clin Oncol,2014,37(1):41-46. DOI:10.1097/COC.0b013e318261084b [8] Laskar S, Bah G, Muckaden MA,et al. Primary diffuse large B-cell lymphoma of the tonsil:is a higher radiotherapy dose required?[J].Cancer,2007,110(4):816-823. [9] Mian M,Ferreri AJ,Rossi Ae, et al. Role of radiotherapy in patients with early-stage diffuse large B-cell lymphoma of Waldeyer′s ring in remission after anthracycline-containing chemotherapy[J]. Leuk Lymphoma,2013,54(1):62-68. DOI:10.3109/10428194.2012.710907 [10] Vaughan-Hudson B,Vaughan-Hudson G,MacLennan KA,et al. Clinical stage Ⅰ non-Hodgkin′s lymphoma:long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy[J]. Br J Cancer,1994,69(6):1088-1093. [11] Phan J, Mazloom A, Medeiros LJ,et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy[J].J Clin Oncol,2010,28(27):4170-4176. DOI:10.1200/JCO.2009.27.3441. [12] Persky DO, Unger JM, Spier CM, et al. Phase Ⅱ study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma:Southwest Oncology Group study 0014[J]. J Clin Oncol,2008,26(14):2258-2263. DOI:10.1200/JCO.2007.13.6929. [13] Ferreri AJ, Dell′Oro S,Reni M,et al. Consolidation radiotherapy to bulky or semibulky lesions in the management of stage Ⅲ－Ⅳ diffuse large B cell lymphomas[J]. Oncology,2000,58(3):219-226. [14] Schlembach PJ,Wilder RB,Tucker SL, et al. Impact of involved field radiotherapy after CHOP-based chemotherapy on stage Ⅲ－Ⅳ, intermediate grade and large-cell immunoblastic lymphomas[J].Int J Radiat Oncol Biol Phys,2000,48(4):1107-1110. [15] Held G,Murawski N,Ziepert M, et al. Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma[J]. J Clin Oncol,2014,32(11):1112-1118. DOI:10.1200/JCO.2013.51.4505. [16] Marcheselli L,Marcheselli R,Bari A, et al. Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma[J]. Leuk Lymphoma,2011,52(10):1867-1872. DOI:10.3109/10428194.2011.585526.
2015, Vol. 24 
